Results 41 to 50 of about 15,396 (178)

Visual hallucination induced by duloxetine use: a male case diagnosed with generalized anxiety disorder

Psychiatry and Clinical Psychopharmacology, 2018
Duloxetine is a serotonin-noradrenaline reuptake inhibitor. It has been increasingly used in child and adolescent psychiatric practice in recent years. In this paper, we presented a 16-year-old male patient diagnosed with generalized anxiety disorder who
Kemal Utku Yazici, Ipek Percinel Yazici
doaj   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Duloxetine-Induced Sleep Bruxism and Tooth Fracture in Fibromyalgia

Düzce Tıp Fakültesi Dergisi
Duloxetine is a serotonin-norepinephrine reuptake inhibitor that is approved for the treatment of fibromyalgia. Duloxetine has many side effects such as nausea, somnolence, insomnia, decreased appetite, dry mouth, and constipation.
İsmail Tunçekin, Murat Toprak
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports

Drug, Healthcare and Patient Safety, 2013
David G Perahia,1 Mark E Bangs,2 Qi Zhang,2 Yingkai Cheng,2 Jonna Ahl,2 Elijah P Frakes,2 Michael J Adams,2 James M Martinez2 1Neurosciences, Lilly Research Centre, Windlesham, Surrey, UK; 2Neurosciences, Eli Lilly and Company, Indianapolis, IN, USA ...
Perahia DG, Bangs ME, Zhang Q, Cheng Y, Ahl J, Frakes EP, Adams MJ, Martinez JM   +7 more
doaj  

Duloxetine reduces opioid consumption and pain after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials

Journal of Orthopaedic Surgery and Research
Purpose There is no consensus in the current literature on the analgesic role of duloxetine after total hip arthroplasty (THA) or total knee arthroplasty (TKA).
Yicai Lin, Mingyang Jiang, Chun Liao, Qingjian Wu, Jinmin Zhao   +4 more
doaj   +1 more source

Effects of fluvoxamine on duloxetine plasma concentrations: A case series

Psychiatry and Clinical Psychopharmacology, 2021
Objective: Duloxetine is metabolized in liver by CYP1A2 enzyme. Concomitant Concomitant use of fluvoxamine, which is an inhibitor of CYP 1A2 enzyme with duloxetine may increase bioavailability of duloxetine from 42,8% to 81.9%, and plasma levels by 141%-
Esra Sağlam, Birim Sungu Danışmant, Gül Eryılmaz, Fadime Canbolat, Kaşif Nevzat Tarhan   +4 more
doaj  

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care

Journal of Pain Research, 2013
Jeffrey Scott Andrews,1 Ning Wu,2 Shih-Yin Chen,2 Xia Yu,2 Xiaomei Peng,1 Diego Novick1 1Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; 2Evidera, Lexington, MA, USA Abstract: To describe the use of pain medications in patients with
Andrews JS, Wu N, Chen SY, Yu X, Peng XM, Novick D   +5 more
doaj  

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source